onc brain

The longer read

The trial targets a question practice had already drifted into answering without randomised evidence. Nodal SBRT for PET-detected pelvic recurrence spread because it is short, targeted and tolerable, while whole-pelvis RT came with the intuition that anything visible on PET is the tip of a regional burden. PEACE V-STORM supports that intuition: the separation is carried by regional control, and the authors trace the MFS difference to prevented M1a nodal spread rather than to fewer bone or visceral events. That mechanism matters for how to read the result. ENRT is not buying systemic control; it is sterilising the pelvic nodal basin that PSMA PET cannot fully resolve, and MDT pts paid for that with repeat salvage (28 received another course of MDT).

The statistical frame deserves weight before the headline does. This is a screening phase 2 with α 0.20 and 80% CIs, and the primary p of 0.063 would not pass a conventional threshold. The direction is consistent across bRFS, locoregional RFS and ADT-free survival, which argues against chance, but the magnitude should be expected to shrink in a confirmatory trial. The authors themselves describe ENRT as a potential standard awaiting phase 3, and POINTER-PC is the trial that will decide it.

The subgroups point where the benefit likely lives. The effect was concentrated in PSMA-staged pts and those with PSA below 1, and absent with choline staging, PSA of 1 or higher, or common iliac involvement. Read together, ENRT seems to help most when disease is truly low-volume and pelvis-confined; once the burden is higher or already near the upper field edge, more lies outside the pelvis and a larger field adds little. Only the tracer split was prespecified, so these are hypothesis-generating, but they are biologically coherent and they narrow the population a reader should extrapolate to.

The prostate bed is the complication in this design. It was left to physician discretion, used more often in the ENRT arm, and in post hoc analysis tracked with both fewer local recurrences and more G2+ GI toxicity. Part of what looks like ENRT tolerability or ENRT benefit may therefore belong to prostate bed decisions rather than the pelvic nodal field. The encouraging finding is that the large pelvic field itself did not raise GI toxicity against SBRT, which weakens the main argument for the smaller field.

Against the ADT-sparing literature the authors cite (RADIOSA, EXTEND, EMBARK), the useful point is that local RT plus a short ADT course in both arms kept most pts off ADT for years. What remains unsettled is survival, which had too few events to report given near-universal cancer-specific survival in this setting, and whether the result survives central PET review and PSMA-only staging.